The longer talks drag on, the less likely it is that lawmakers attach policy riders to the reauthorization of FDA user fees in stop-gap spending legislation, drug lobbyists said, and lawmakers already missed two self-imposed deadlines for a deal. There’s talk of instead attaching FDA policy riders to omnibus appropriations legislation during the lame-duck session, but lobbyists said that would be difficult to pull off. There are still negotiations over policy riders, but lobbyists said the only ones with much...